ELV vs UNH

Key Takeaways

• UNH has staged a dramatic recovery from its 2025 crisis, gaining over 30% year-to-date through mid-2026, while ELV has delivered more modest but steadier returns of roughly 13% over the same period.
• Both companies face a persistent industry-wide headwind of elevated medical cost trends, with medical loss ratios (MLR — the percentage of premium revenue spent on medical care) compressing margins across the managed care sector.
• UnitedHealth's Optum platform provides a diversified, higher-margin services engine that Elevance's younger Carelon segment is still in the process of scaling, creating a meaningful structural difference between the two business models.
• ELV trades at a notably lower forward price-to-earnings (P/E) multiple of approximately 15.7x versus UNH's elevated ratio above 30x, suggesting a valuation gap that reflects differing market sentiment and growth expectations.
• UNH's 2025 included a series of extraordinary setbacks — a leadership change, suspended guidance, and a historic stock decline — while ELV navigated the same cost environment with comparatively less volatility.
• The two stocks maintain a moderate correlation of approximately 0.60 over the past year, meaning they share common sector drivers but diverge enough to offer distinct risk-return profiles for portfolio positioning.

Introduction

Elevance Health and UnitedHealth Group represent two of the largest and most closely watched names in the U.S. managed care industry. Both companies sit at the intersection of health insurance and healthcare services, operating in a sector that has faced intense scrutiny over the past year due to rising medical utilization, shifting regulatory frameworks, and evolving reimbursement models. For investors evaluating exposure to healthcare, the choice between these two stocks is far from trivial. ELV and UNH differ meaningfully in scale, business mix, recent stock behavior, and strategic direction — and those differences have become more pronounced against the backdrop of an industry grappling with what executives have described as an "unprecedented medical cost trend environment." This comparison is designed to give traders and long-term investors a clear, data-driven view of where each company stands today.

ELV Overview and Recent Performance

ELV, formerly known as Anthem and rebranded as Elevance Health in 2022, is headquartered in Indianapolis, Indiana, and serves approximately 46 million members through its Health Benefits segment. The company also operates CarelonRx, its pharmacy services arm, and Carelon Services, a growing platform focused on behavioral health, care management, and data analytics. Elevance reported full-year 2025 revenue of approximately $199.1 billion, representing a 12.6% year-over-year increase, driven by higher premium yields and recent acquisitions. However, earnings came under pressure: adjusted diluted EPS (earnings per share) guidance for 2025 was revised down to approximately $30.00, reflecting elevated medical cost trends in the company's ACA (Affordable Care Act) marketplace and Medicaid businesses. In recent weeks, the stock has traded in the $370–$420 range, with a one-year return exceeding 25%. Market sentiment has been shaped by the broader managed care sell-off and by analyst actions — including a downgrade from Buy to Hold by Argus Research in mid-2025 — though ELV's diversified business mix and disciplined cost management have provided a degree of resilience relative to some peers.

UNH Overview and Recent Performance

UNH is the largest health insurer in the United States by revenue and market capitalization, with its UnitedHealthcare division covering over 47 million members and its Optum segment spanning pharmacy benefit management, care delivery, and health data analytics. UnitedHealth's 2025 was marked by extraordinary turbulence: the company suspended its full-year outlook in May 2025 amid soaring Medicare Advantage costs, its stock plummeted approximately 62% from its November 2024 all-time high to its August 2025 trough, CEO Andrew Witty resigned, and the company ultimately reinstated guidance well below Wall Street expectations — with adjusted EPS of at least $16.00 versus a prior range of $26.00 to $26.50. Since the start of 2026, however, UNH has engineered a notable turnaround. The stock has surged more than 30% year-to-date, boosted by a deliberate strategic pivot toward margin restoration over membership growth, a 2.48% Medicare Advantage rate increase for 2027, and improved medical cost ratios in recent quarters. The recovery has been powerful but has pushed UNH's P/E multiple above 30x, reintroducing valuation questions even as momentum remains positive.

Trending AI Robots

In a market environment as dynamic as the one facing healthcare stocks today, many traders are turning to AI-powered tools to help navigate the complexity. Tickeron's Trending AI Robots page features a curated selection of the platform's most capable AI trading bots — chosen from a universe of hundreds of bots that trade thousands of different tickers — based on their real-time alignment with current market conditions. Each bot operates with its own distinct trading style, strategy, timeframe, and statistical profile, ranging from short-term momentum models to longer-duration trend-following systems. The bots' historical performance metrics, including win rates, trade frequency, and drawdown characteristics, offer transparency that can help users evaluate which approach may suit their objectives. Only those bots demonstrating the strongest adaptability to prevailing market regimes earn a place in the Trending section, making it a useful starting point for traders who want to explore algorithmic strategies without sifting through the full library. Explore the Trending AI Robots to see which strategies are resonating with today's markets.

Head-to-Head Comparison

When placed side by side, ELV and UNH reveal a contrast between steady operational execution and high-volatility recovery. The most immediate difference is scale: UNH's revenue of roughly $447.6 billion in 2025 is more than double ELV's $199.1 billion, and its market capitalization of approximately $236 billion dwarfs ELV's roughly $80–91 billion. UNH's Optum platform — spanning pharmacy services (Optum Rx), care delivery (Optum Health), and health data analytics (Optum Insight) — represents a deeply integrated, high-margin complement to its insurance business. ELV's Carelon segment is built on a similar thesis but remains at an earlier stage of maturity, making it a smaller contributor to consolidated earnings.

From a risk perspective, UNH has experienced a wider range of outcomes over the past year: a 62% peak-to-trough decline followed by a sharp recovery of more than 57% from its March 2026 lows. ELV, by contrast, has traded in a narrower band, with a 52-week range that reflects a less volatile — though still challenged — trajectory. Both companies currently post compressed net profit margins of roughly 2.6%–2.7%, well below their respective five-year averages, underscoring the shared challenge of rising medical costs. Dividend-oriented investors may note that UNH offers a higher trailing yield of approximately 2.3% compared to ELV's roughly 1.7%, while value-conscious investors may find ELV's forward P/E of roughly 15.7x more attractive than UNH's elevated multiple.

Sector exposure is another point of differentiation. Both companies participate in Medicare Advantage, Medicaid managed care, employer-sponsored plans, and ACA individual markets, but UNH's deliberate decision to accept near-term membership declines in pursuit of margin recovery marks a distinct strategic posture. ELV has taken its own portfolio actions but has generally maintained a steadier membership trajectory, particularly through its Blue Cross Blue Shield branded plans. The regulatory environment — including the recently finalized 2.48% Medicare Advantage rate increase for 2027 — serves as a tailwind for both, though UNH's larger MA footprint means it captures proportionally more of that benefit.

Tickeron AI Verdict

Based on the observable data, Tickeron's AI-driven analytical framework would likely express a measured preference for ELV at current levels, though with important caveats. While UNH has demonstrated stronger recent momentum and a compelling recovery narrative, its P/E expansion above 30x introduces valuation risk that trend-following models typically monitor closely. ELV's steadier price action, lower beta of 0.68, more moderate valuation multiple, and consistent execution through the same industry headwinds suggest a relatively more balanced risk-reward profile. The AI would likely acknowledge that UNH's Optum platform and market leadership provide structural advantages that could support long-term outperformance, but in the current environment — where both names face persistent medical cost pressures and compressed margins — the combination of ELV's lower volatility, reasonable valuation, and diversified business mix may offer a more favorable probabilistic setup. As always, the AI's assessment reflects a snapshot of current conditions and is not a prediction of future price movement.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations